Jagsonpal Pharmaceuticals Limited announces an acquisition

The acquisition broadens Jagsonpal’s strategic mix toward consumer wellness, but it does not represent a clear shift from prescription products into OTC revenue. The acquired portfolio is described as a complementary Rx-branded-generic portfolio within the broader wellness category, comprising two brands and six SKUs, with FY26 revenue of approximately Rs 24.6 Crores.^[5]

Revenue mix impact

Implication: the transaction adds a consumer-facing wellness layer and creates cross-selling opportunities through Jagsonpal’s field force and distribution network, but the immediate revenue effect is more accurately characterized as additional Rx-branded revenue with wellness positioning, rather than a wholesale migration toward OTC products.^[9]

Jagsonpal already operates across branded generics, trade generics and OTC, but it has not separately disclosed the percentage contribution of each category before and after the acquisition.^[10] Therefore, the precise change in Rx versus OTC/wellness revenue contribution cannot be quantified from the disclosed information.

The Group Pharmaceuticals wellness portfolio was acquired at approximately 0.96x FY26 sales on the upfront consideration, rising to approximately 1.90x sales if the maximum earn-out is paid. The disclosed upfront consideration was Rs 23.7 Crores, with an additional Rs 23.0 Crores linked to FY28 sales, against FY26 revenue of approximately Rs 24.6 Crores. ^[5]

These are enterprise-value proxies, assuming the disclosed consideration represents the economic purchase price and that no material debt, cash, or other balance-sheet adjustments need to be added. The transaction was structured as a going-concern business transfer, so the strict EV bridge is not fully disclosed. ^[11]

EV/EBITDA cannot be calculated from the disclosed operating data. FY26 EBITDA for the acquired portfolio was not reported. The Rs 10 Crores EBITDA target appearing in the broader presentation relates to the Aequitas Healthcare value-creation roadmap, not an explicitly disclosed FY26 EBITDA for the Group Pharmaceuticals portfolio. ^[12]

Benchmark against comparable transactions

A transaction-level benchmark against recent Indian domestic-formulations deals cannot be established from the cited material: no comparable deal consideration, acquired revenue, or EBITDA data is provided for the named peer set. Accordingly, the defensible conclusion is limited to the deal’s own valuation:

• Upfront pricing: below 1.0x historical sales, which is a relatively modest entry multiple for a branded portfolio, but is based on historical revenue rather than profit.
• Maximum pricing: close to 1.9x historical sales, making the earn-out economics important; the final valuation depends on whether the acquired brands deliver the FY28 sales trigger.
• Key limitation: without portfolio EBITDA, margins, and the earn-out threshold mechanics, the transaction cannot be ranked meaningfully against domestic-formulations acquisitions on EV/EBITDA or like-for-like sales multiples.

_Scope note: this comparison also included Jagsonpal Pharmaceuticals Limited (JAGSNPHARM); Amrutanjan Health Care Limited (AMRUTANJAN); Fermenta Biotec. (FERMENTA); Anlon Healthcare (AHCL); Kopran (KOPRAN); NGL Fine Chem (NGLFINE), which the answer above does not cover. Ask about any of them for a full side-by-side._